Overview

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
2024-02-29
Target enrollment:
Participant gender:
Summary
The overall objective of this Phase 1 study is to evaluate the safety, PK, and anti-tumor activity of 12 weeks of daily oral dosing with HP518 after selecting the RP2D of HP518 based on assessments of multiple dose escalation in patients with progressive mCRPC.
Phase:
Phase 1
Details
Lead Sponsor:
Hinova Pharmaceuticals Aus Pty Ltd